In their 2018 study published in Nature Medicine, Chapuy et al. conducted a comprehensive genetic analysis of 304 primary diffuse large B-cell lymphoma (DLBCL) samples. Through integrative analysis of somatic mutations, copy number alterations, and structural variants, they identified five distinct molecular subtypes of DLBCL, labeled C1 through C5, each characterized by unique genetic alterations and associated clinical outcomes.

1. C1 Subtype:

   • Characterized by mutations in NOTCH2 and BCL6.
   • Suggests an extrafollicular/marginal zone origin.

2. C2 Subtype:

   • Defined by biallelic inactivation of TP53 and CDKN2A loss.
   • Associated with genomic instability.

3. C3 Subtype:

   • Enriched for BCL2 translocations and mutations in chromatin modifiers such as EZH2.
   • Indicates a germinal center B-cell origin.

4. C4 Subtype:

   • Marked by mutations in SGK1, BRAF, and STAT3.
   • Associated with a favorable prognosis.

5. C5 Subtype:

   • Characterized by co-mutations in MYD88 and CD79B.
   • Associated with chronic active B-cell receptor signaling.

• The study demonstrated that these molecular subtypes correlate with distinct survival outcomes, independent of the traditional International Prognostic Index (IPI).
• Findings suggest potential for subtype-specific therapeutic strategies, emphasizing the need for personalized treatment approaches in DLBCL.

Subsequent analyses have validated the existence of these molecular subtypes and their clinical relevance. However, some studies have noted challenges in replicating the exact classification due to differences in sequencing techniques and cohort compositions. Additionally, the dynamic nature of DLBCL genetics necessitates continuous refinement of these subtypes to incorporate emerging genetic data.

Chapuy et al.'s study significantly advanced the understanding of DLBCL heterogeneity by identifying molecular subtypes with distinct genetic and clinical features. These insights have paved the way for more targeted therapeutic interventions, although ongoing research is essential to refine these classifications and translate them into clinical practice effectively.

---
config:
    sankey:
        showValues: true
        linkColor: target
        width: 600
        height: 300
        nodeAlignment: right
        prefix: '('
        suffix: ' genes)'
---
sankey-beta
This study, New Tier 1, 10
New Tier 1, DLBCL Tier 1, 10
This study, New Tier 2, 13
New Tier 2, DLBCL Tier 2, 13
This study, New Tier 3, 6
New Tier 3, DLBCL Tier 3, 6
All other DLBCL studies, DLBCL Tier 1, 115
All other DLBCL studies, DLBCL Tier 2, 197
All other DLBCL studies, DLBCL Tier 3, 381